By Counterforce Health Team in Keytruda (pembrolizumab) —

How to Get Keytruda (pembrolizumab) Covered by Aetna (CVS Health) in Florida: Renewal Guide, Appeal Scripts, and Timeline

Quick Answer: Getting Keytruda (pembrolizumab) Covered by Aetna (CVS Health) in Florida

Aetna (CVS Health) requires prior authorization for Keytruda in Florida, with specific forms for commercial vs. Medicare plans. For renewals, submit updated clinical evidence showing continued benefit 6-8 weeks before your current authorization expires. If denied, you have 180 days to appeal internally and 4 months for external review. Start by having your oncologist complete the Keytruda Injectable Medication Precertification Request form with recent imaging, labs, and biomarker results.

Table of Contents

Coverage Requirements at a Glance

Requirement Details Source
Prior Authorization Required for all Aetna plans 2024 Precert List
Formulary Status Covered specialty drug, non-preferred for some indications Clinical Policy Bulletin
Renewal Frequency Every 6-12 months with clinical documentation Medicare Form
Site of Care May require specific infusion centers Drug Infusion Policy
Appeals Deadline 180 days from denial (Florida) Provider Appeals

Renewal Triggers: When to Start Early

Standard Timing Windows

Start your renewal process 6-8 weeks before your current authorization expires. Aetna typically approves Keytruda for 6-12 month periods, and you'll want to avoid any treatment gaps.

Signs You Should Start Immediately

  • Your authorization expires within 60 days
  • You're approaching the 24-month treatment limit for your indication
  • Recent imaging shows new lesions or progression
  • You've experienced significant immune-related side effects
  • Your insurance plan is changing for the next year
Tip: Most oncology practices track authorization expiration dates, but it's wise to keep your own calendar reminder set for 8 weeks before expiration.

Evidence Update: What Your Doctor Needs

Response to Therapy Documentation

Your oncologist must document continued clinical benefit through:

  • Recent imaging (within 8-12 weeks) showing stable disease, partial response, or complete response
  • Tumor markers if applicable to your cancer type
  • Clinical assessment of symptoms, performance status, and quality of life

Adverse Events Monitoring

Aetna expects documentation of:

  • Laboratory monitoring: liver enzymes (AST/ALT), kidney function (creatinine), and thyroid function (TSH, free T4) as required by the FDA label
  • Immune-related adverse events: how any side effects were managed and why treatment can safely continue
  • Dose modifications: if treatment was held or delayed, and the clinical rationale for resuming

Renewal Packet: Must-Include Documents

For Commercial Plans

Use the Keytruda Injectable Medication Precertification Request form (GR-69035) and include:

  1. Continuation of therapy box checked with last treatment date
  2. Primary and secondary ICD-10 codes for your cancer diagnosis
  3. Complete medication regimen including supportive care drugs
  4. Biomarker results if required (PD-L1 expression, MSI-H/dMMR status, TMB-high)
  5. Recent oncology notes with treatment response assessment
  6. Current imaging reports (within 3 months)
  7. Laboratory results showing safe continuation of therapy

For Medicare Advantage Plans

Use the Medicare Keytruda Medication Precertification Request form with the same clinical documentation plus confirmation that you haven't had prior Keytruda therapy in the last 365 days (unless this is a continuation).

Timeline: Submission to Decision

Standard Processing

  • Submission: Fax to 1-888-267-3277 or submit via Aetna provider portal
  • Initial review: 5-7 business days for complete submissions
  • Standard decision: Up to 30 calendar days for commercial plans
  • Medicare decisions: Up to 30 days for pre-service, 60 days for post-service

Expedited Processing

For urgent situations where delay could jeopardize your health:

  • Request expedited review on the form and in your doctor's letter
  • Decision timeline: Within 72 hours
  • Qualification criteria: Life-threatening condition, severe unmanaged symptoms, or ongoing treatment interruption

If Coverage Lapses: Bridge Options

Immediate Steps

  1. Contact your oncologist immediately if you miss a scheduled infusion
  2. Request expedited appeal if the delay was due to authorization issues
  3. Explore manufacturer support through Merck's Keytruda Access Program

Bridge Programs to Discuss

  • Merck patient assistance programs for eligible patients
  • Hospital charity care if you receive infusions at a hospital-based center
  • CVS Specialty pharmacy coordination for alternative coverage sources
Note: Never stop treatment without discussing alternatives with your oncologist, as interruptions can affect treatment effectiveness.

Annual Changes: What to Re-Verify

January 1st Plan Updates

Each year, verify:

  • Formulary status: Keytruda's tier placement and any new restrictions
  • Prior authorization criteria: Updated biomarker requirements or indication limits
  • Preferred alternatives: Whether Aetna now prefers Libtayo (cemiplimab) for your indication
  • Site of care requirements: Changes to preferred infusion centers

Mid-Year Changes

Aetna can modify coverage requirements mid-year with proper notice. Watch for:

  • Summary of Changes documents from Aetna
  • Provider bulletins about new utilization management policies
  • Formulary updates affecting specialty oncology drugs

Appeals Playbook for Florida

Internal Appeals Process

Timeline: 180 days from denial notice to file appeal

Standard Appeal Decision: 30 days for commercial plans, 30-60 days for Medicare

Expedited Appeal Decision: 72 hours when medically urgent

Required Documentation

  1. Completed appeal form with clear medical necessity argument
  2. Physician letter addressing specific denial reasons
  3. Clinical evidence supporting continued treatment
  4. Guidelines citations from NCCN, FDA label, or specialty societies

External Review (After Final Denial)

Timeline: 4 months from final internal denial

Process: Independent review by Florida Department of Financial Services

Cost: Free to patients

Contact: Florida Division of Consumer Services at 1-877-693-5236

Important: Florida law requires insurers to provide external review rights. The decision is binding on Aetna if the external reviewer finds in your favor.

Common Denial Reasons & Solutions

Denial Reason How to Overturn
"Not medically necessary" Provide NCCN guidelines showing Category 1/2A recommendation for your indication
"Experimental/investigational" Submit FDA label language and peer-reviewed efficacy studies
"Off-label use" Include drug compendium citations and specialty society guidelines
"Step therapy not completed" Document prior therapy failures, intolerances, or contraindications
"Quantity limits exceeded" Provide dosing rationale based on FDA label or weight-based calculations

Scripts for Patients and Clinics

Patient Phone Script for Aetna

"Hello, I'm calling about prior authorization for Keytruda, pembrolizumab, for [your name], member ID [number]. My oncologist submitted a renewal request on [date]. Can you tell me the status and what additional information might be needed? I'd also like to know if I qualify for expedited review given my cancer diagnosis."

Clinic Staff Script for Peer-to-Peer

"I'm requesting a peer-to-peer review for [patient name] regarding the denial of pembrolizumab continuation. The patient has [cancer type] with [biomarker status] and has shown [response type] on current therapy. The denial cited [reason]. I have additional clinical information that supports medical necessity. When can we schedule this review?"

FAQ: Keytruda (pembrolizumab) Coverage

How long does Aetna prior authorization take in Florida? Standard decisions take up to 30 days; expedited reviews are completed within 72 hours for urgent medical situations.

What if Keytruda is non-formulary on my plan? You can request a formulary exception with documentation that preferred alternatives are inappropriate or have failed.

Can I request an expedited appeal? Yes, if delay in treatment could seriously jeopardize your health or ability to regain maximum function—which typically applies to cancer treatments.

Does step therapy apply if I've tried other treatments outside Florida? Yes, document all prior therapies regardless of where they were received. Include records of failures, intolerances, or contraindications.

What happens if I switch from commercial to Medicare mid-treatment? You'll need new prior authorization using Medicare-specific forms, but continuation of effective therapy is generally approved.

How do I find Aetna's preferred infusion centers? Check your provider directory or call member services to confirm which facilities meet site-of-care requirements.

About Counterforce Health: Counterforce Health specializes in turning insurance denials into successful appeals for specialty medications like Keytruda. Our platform analyzes denial letters and creates targeted, evidence-based appeals that align with each payer's specific requirements, helping patients navigate complex prior authorization processes more effectively.

When dealing with complex specialty drug approvals, having expert support can make the difference between a successful authorization and months of delays. Counterforce Health has helped numerous patients in Florida secure coverage for critical cancer treatments by providing the detailed clinical documentation and policy-specific arguments that payers expect.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider about treatment decisions and contact your insurance company directly for the most current coverage information. Coverage policies and appeal procedures may vary by plan and can change over time.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.